MultiCell Technologies has developed an exclusive proprietary process for indefinitely growing healthy "immortalized" human liver cells which can be grown quickly in large batches for use by the pharmaceutical industry and research institutions worldwide to expedite drug discovery development and drastically reduce R&D costs. These immortalized human liver cells function much as they would in living persons and are used by researchers to test toxicity of experimental compounds before expensive and potentially dangerous testing on humans. The market for these humanized cells is estimated to be in the billions of dollars which has really caught our attention. In addition, these replicable healthy human cells can produce various proteins, etc., which have the potential to be used and engineered for other therapeutic uses which MultiCell is also investigating.
MultiCell recently signed a 15-year agreement to supply these cells to Pfizer Pharmaceuticals and has also just signed another agreement with a premier privately held cellular biotech manufacturing and marketing firm to begin producing and marketing its immortalized human liver cells to other pharmaceutical firms in the U.S., Europe and Japan.
News 
Market Data 
Discover 
AI
